Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly (LLY) CEO Dave Ricks said Friday that ... loss — both of which are administered by injection. “We’re building inventory so that when we introduce [orforglipron] in 2026, we can ...

Eli Lilly CEO David Ricks speaks during a press conference, on the day of a groundbreaking ceremony to mark the beginning of the construction of the new plant, in Alzey, Germany, April 8, 2024. Lilly ...

A report from Ozmosi estimates that seven new GLP-1 agonists could launch in the U.S. by 2030. Competition isn't ideal for Eli Lilly ... company dedicated to building the world's greatest ...

Eli Lilly released new data around a daily weight-loss pill ... We're gonna make this medicine here in the United States. We're building the largest, what we call API factory, which is ...

Eli Lilly is a veteran of the industry ... Trump's stated plans to impose tariffs on imported goods, Lilly has been building new facilities in the U.S. (or improving existing ones) for years.

Eli Lilly & Co. plans to manufacture its new weight-loss pill in the US for patients around ... But Lilly is already ...

However, the White House has certainly been dropping some breadcrumbs making executives at pharma giants wary that new tariffs could ... stocks to own has been Eli Lilly (NYSE: LLY).

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...